GET IN TOUCH

Aragen Life Sciences develops and manufactures small molecule drug substances, also called APIs (active pharmaceutical ingredients). We supply key starting materials (KSMs), advanced intermediates and APIs in non-GMP and GMP grades, from kilo lab to plant scale.

We support programs from IND-enabling toxicology studies through global clinical trials to commercial supply. Our focus is faster timelines without compromising quality or regulatory compliance.

Our experienced team adeptly navigates potential challenges in both early and late-stage drug substance development. This proactive approach ensures smooth technology transfer from preclinical supply to commercial manufacturing, reducing drug substance.

At Aragen, our team follows a scientific and data-driven approach (QbD approach) for drug substance process development, by understanding all the critical process parameters and operations using DOE methodology and in-line PAT technology. This creates an optimum design space ensuring process robustness and reproducibility from laboratory scale to manufacturing.

Our expert process engineering team at Aragen follows a systematic and technical approach during technology transfer, considering necessary engineering studies with respect to all scale-up parameters. This helps identify potential risks and implement a risk mitigation plan, ensuring smooth and reproducible execution of the drug substance manufacturing process.

Our extensive project experience allows us to streamline your drug substance development process, supporting your needs from the IND-enabling pharm-tox stage through global clinical trials. We focus on accelerating timelines without compromising on quality or regulatory compliance.

Seamless integration across multiple functions, including EHS, project management, quality control, quality assurance, regulatory, and supply chain management, drives operational excellence. We ensure that customer expectations are met on quality, quantity, and on-time supply of drug substances.

Early Phase

Late Phase

Commercial

Our Value Proposition
Aragen drug substance value proposition infographic: route scouting and process chemistry, impurity synthesis and control, GLP tox and NGMP/GMP manufacturing, speed in early phase, stability and IND/DMF filing support, process safety and engineering, green chemistry

Our value proposition lies in our experienced and talented team, adept at managing cross-functional transitions effectively. This expertise facilitates efficient and swift project progression from pre-IND to NDA and beyond through strong cross-functional linkages. Our development philosophy emphasizes phase-appropriate development, prioritizing speed in early phases, and early evaluation of regulatory, safety, and engineering aspects. We are committed to creating safe, robust, and scalable processes with a constant focus on sustainable and green opportunities.

Our Approach
Aragen drug substance approach infographic: dynamic and innovative mindset, extensive direct experience, proactive approach, seamless technology transfer and IND-enabling pharm-tox to global clinical trials

Operational Excellence

Seamless integration across multiple functions, including Environmental Health and Safety (EHS), project management, quality control, quality assurance, regulatory affairs, and supply chain management, is at the core of our operational excellence. We are committed to delivering drug substances that meet agreed quality standards, required quantities, and customer timelines.

Frequently Asked Questions (FAQs)

A key starting material (KSM) is a raw material that becomes part of an API's structure. Aragen supplies KSMs in non-GMP and GMP grades.

Quality by Design (QbD) means designing the process around a clear understanding of its critical parameters, using tools such as DoE and PAT.

From kilo lab to plant scale.

Early phase, late phase and commercial.

Our Drug Substance
Solutions